Drug Profile
SQN 400
Alternative Names: BacteriochlorinLatest Information Update: 14 Mar 2019
Price :
$50
*
At a glance
- Originator Scotia Holdings
- Developer biolitec; QuantaNova
- Class Antineoplastics; Porphyrins; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 14 Mar 2019 Chemical structure information added
- 11 Mar 2019 Discontinued - Phase-II for Liver cancer in Germany (unspecified route)
- 22 Jan 2002 QuantaNova has the photodynamic therapy assets of Scotia Holdings